Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study
Michael S. Cookson(University of Oklahoma Health Sciences Center), William R. Fair(University of California System), Paul Russo(Memorial Sloan Kettering Cancer Center), Colin B. Begg(Memorial Sloan Kettering Cancer Center), Pramod C. Sogani(Memorial Sloan Kettering Cancer Center), Joel Sheinfeld(Memorial Sloan Kettering Cancer Center), Victor E. Reuter(Memorial Sloan Kettering Cancer Center), H.W. Herr(Memorial Sloan Kettering Cancer Center), Guido Dalbagni(Memorial Sloan Kettering Cancer Center)
Cited by 39
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Clinical-grade computational pathology using weakly supervised deep learning on whole slide images
|Nature Medicine|2019|2.6k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Racial Differences in the Treatment of Early-Stage Lung Cancer
|New England Journal of Medicine|1999|1k